

# BEP15

## (Bleomycin, etoposide, cisplatin)

### Indication

Germ cell tumour with poor prognosis (for use following induction with CBOP regimen only)

### Regimen details

Day	Drug	Fluid	Time
1	Etoposide 100mg/m <sup>2</sup>	1 litre sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
	Cisplatin 20mg/m <sup>2</sup>	500ml Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
2	Hydrocortisone 200mg IV bolus		
	Bleomycin 15,000 units	250ml Sodium chloride 0.9%	30 min
	Etoposide 100mg/m <sup>2</sup>	1 litre Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
	Cisplatin 20mg/m <sup>2</sup>	500ml Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
3	Etoposide 100mg/m <sup>2</sup>	1 litre Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
	Cisplatin 20mg/m <sup>2</sup>	500ml Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
4	Etoposide 100mg/m <sup>2</sup>	1 litre Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
	Cisplatin 20mg/m <sup>2</sup>	500ml Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
5	Etoposide 100mg/m <sup>2</sup>	1 litre Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours
	Cisplatin 20mg/m <sup>2</sup>	500ml Sodium chloride 0.9%	1 hour
	20mmol Potassium chloride + 10mmol Magnesium sulphate	1 litre Sodium chloride 0.9%	2 hours

Day	Drug	Fluid	Time
8	Hydrocortisone 200mg IV bolus		
	Bleomycin 15,000 units	250ml Sodium chloride 0.9%	30 minutes
15	Hydrocortisone 200mg IV bolus		
	Bleomycin 15,000 units	250ml Sodium chloride 0.9%	30 minutes

### Cycle frequency

Every 21 days

### Number of cycles

3 cycles

### Administration

Strict fluid balance

Consider frusemide 20-40mg p.o/IV if >1000ml positive balance

Do not wait for results of FBC prior to giving day 8, 15 treatments unless patient looks unwell or is pyrexial.

### Pre-medication

Hydrocortisone 200mg IV bolus before bleomycin

### Emetogenicity

Highly emetogenic (days 1-5)

Minimally emetogenic (days 8 & 15)

### Additional supportive medication

Filgrastim 5mcg/kg sc daily for 7 days starting day 7

### Investigations – pre first cycle

Creatinine clearance

FBC, U&E, LFT incl. LDH, Uric Acid, Mg, Ca, AFP, bHCG

### Investigations –pre subsequent cycles

**Weekly:**

FBC

U&E, LFT incl. LDH, Uric Acid, Mg, Ca, AFP, bHCG

### Day 1 only:

Chest X-ray (if metastases present or primary mediastinal germ cell tumour)

Measured GFR only if calculated clearance <60 ml/min (Cockcroft formula)

Do not wait for results of FBC prior to giving day 8, 15 treatments unless patient looks unwell or is pyrexial.

### Standard limits for administration to go ahead

Any Hb (transfuse if < 9.0g/dl)

Platelets > 50 (contact consultant if lower!)

WCC > 1.5 or Neutrophils > 0.5

Creatinine clearance ≥ 50ml/min

**ANY DEFERRAL NEEDS TO BE DISCUSSED WITH CONSULTANT AS TREATMENT DELAYS HAVE NEGATIVE EFFECT ON OUTCOME**

### **Dose modifications**

GFR < 50ml/min or Neurotoxicity > grade 2

Replace Cisplatin with Carboplatin AUC 6

Bleomycin rash/lung toxicity, omit Bleomycin, get HRCT urgently

### **Adverse effects –**

for full details consult product literature/ reference texts

Nausea/vomiting

Alopecia

Infertility (some reversibility within 2 years of treatment)

Mucositis

Cough/SOB (watch out for bleomycin pneumonitis!)

Skin rash

Peripheral neuropathy

Ototoxicity (tinnitus/deafness)

Renal toxicity, electrolyte disturbance (especially magnesium loss)

Myelosuppression

---

**THIS PROTOCOL HAS BEEN DIRECTED BY DR BIRTLE, DESIGNATED LEAD CLINICIAN FOR GERM CELL TUMOURS**

**RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE**

Date: July 2020

Review: July 2022

VERSION: 2

---